Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Cureus
|
January 30, 2016
Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
Tania Jain, Alan Bryce
JCO Precision Oncology
|
March 12, 2026
Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes Analysis
Charles Swanton, Alan Bryce, Allen L Cohn, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 25, 2022
Radiation Therapy in Oligometastatic Prostate Cancer
Siven Chinniah, Bradley Stish, Brian A Costello, et al.
Prostate Cancer and Prostatic Diseases
|
September 27, 2024
Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)
Anthony V Serritella, Amy Taylor, Michael C Haffner, et al.
Journal for Immunotherapy of Cancer
|
August 14, 2020
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
Pedro Barata, Neeraj Agarwal, Roberto Nussenzveig, et al.
Urologic Oncology
|
February 6, 2017
A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study
Rahul Aggarwal, Alan Bryce, Charles J Ryan, et al.
Scientific Reports
|
May 11, 2018
Evaluation of pre-analytical factors affecting plasma DNA analysis
Havell Markus, Tania Contente-Cuomo, Maria Farooq, et al.
The Prostate
|
May 10, 2022
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805
Alicia K Morgans, Yu-Hui Chen, David F Jarrard, et al.
European Urology
|
October 29, 2024
What's in a Name? Why Words Matter in Advanced Prostate Cancer
William K Oh, Neeraj Agarwal, Alan Bryce, et al.
Communications Medicine
|
December 2, 2024
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers
Reagan M Barnett, Albert Jang, Sree Lanka, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Cureus
|
January 30, 2016
Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
Tania Jain, Alan Bryce
JCO Precision Oncology
|
March 12, 2026
Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes Analysis
Charles Swanton, Alan Bryce, Allen L Cohn, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 25, 2022
Radiation Therapy in Oligometastatic Prostate Cancer
Siven Chinniah, Bradley Stish, Brian A Costello, et al.
Prostate Cancer and Prostatic Diseases
|
September 27, 2024
Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)
Anthony V Serritella, Amy Taylor, Michael C Haffner, et al.
Journal for Immunotherapy of Cancer
|
August 14, 2020
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
Pedro Barata, Neeraj Agarwal, Roberto Nussenzveig, et al.
Urologic Oncology
|
February 6, 2017
A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study
Rahul Aggarwal, Alan Bryce, Charles J Ryan, et al.
Scientific Reports
|
May 11, 2018
Evaluation of pre-analytical factors affecting plasma DNA analysis
Havell Markus, Tania Contente-Cuomo, Maria Farooq, et al.
The Prostate
|
May 10, 2022
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805
Alicia K Morgans, Yu-Hui Chen, David F Jarrard, et al.
European Urology
|
October 29, 2024
What's in a Name? Why Words Matter in Advanced Prostate Cancer
William K Oh, Neeraj Agarwal, Alan Bryce, et al.
Communications Medicine
|
December 2, 2024
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers
Reagan M Barnett, Albert Jang, Sree Lanka, et al.
Page
of 3